Advancing a future where scientific insight translates into more accessible, personalized cancer care.
Explore our mission
Our mission is to advance precision medicine for underserved patients by connecting scientific innovation with the realities of care.
We are focused on the development and translation of technologies that can support personalized oncology, inform clinical collaboration, and improve therapeutic delivery. Access is a guiding consideration from the earliest stages of our work.
Three connected areas guide our research and development interests.
Exploring how genomic and diagnostic information can contribute to a deeper understanding of each patient's cancer.
Our interests span molecular diagnostics and the interpretation of complex biological information in its clinical context.
Exploring digital approaches that help multidisciplinary teams bring evidence and expertise into the same conversation.
Future directions include virtual tumor board support and clinician-directed decision support. Clinical judgment remains central.
Investigating opportunities at the intersection of medical devices, therapeutics, and the patient experience.
Our interests include precision drug delivery and technologies that may support treatment beyond conventional care settings.
These areas describe our development interests. They do not represent commercially available products or validated clinical capabilities.
Prioritize meaningful gaps in care, including the barriers faced by underserved communities.
Shape development around clinical relevance, careful validation, and the requirements of responsible translation.
Consider affordability, usability, and care settings alongside technological potential.
Bringing biomedical innovation, product development, and commercialization into a shared perspective.
Founder & CEO
Jyotsna brings more than 25 years of biomedical industry leadership across medical devices, diagnostics, drug-device combinations, and precision oncology.
Her experience includes senior leadership at Roche Tissue Diagnostics, Singular Genomics, Johnson & Johnson, Sanofi, and Medtronic, spanning research and development, operations, and commercialization.
Our mission calls for perspectives from clinical care, research, technology development, and organizations working to expand access.
We are developing in stealth. This website shares our mission and broad areas of focus; technical disclosures are reserved for appropriate confidential discussions.